

Niels D Prins

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5409726/publications.pdf>

Version: 2024-02-01

115
papers

7,617
citations

136950

32
h-index

58581

82
g-index

126
all docs

126
docs citations

126
times ranked

9574
citing authors

#	ARTICLE	IF	CITATIONS
1	The natural history of primary progressive aphasia: beyond aphasia. <i>Journal of Neurology</i> , 2022, 269, 1375-1385.	3.6	23
2	Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria. <i>Alzheimer's and Dementia</i> , 2022, 18, 810-823.	0.8	38
3	Neuropsychiatric Symptoms as Predictor of Poor Clinical Outcome in Patients With Vascular Cognitive Impairment. <i>American Journal of Geriatric Psychiatry</i> , 2022, , .	1.2	1
4	Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline. <i>Neurology</i> , 2022, 98, .	1.1	41
5	Diversity in Alzheimer's disease drug trials: Reflections on reporting and social construction of race. <i>Alzheimer's and Dementia</i> , 2022, 18, 867-868.	0.8	3
6	Vascular Cognitive Impairment and cognitive decline; a longitudinal study comparing different types of vascular brain injury - The TRACE-VCI study. <i>Cerebral Circulation - Cognition and Behavior</i> , 2022, 3, 100141.	0.9	2
7	Decreased integrity of the monoaminergic tract is associated with a positive response to MPH in patients with vascular cognitive impairment - proof of principle study STREAM-VCI. <i>Cerebral Circulation - Cognition and Behavior</i> , 2022, 3, 100128.	0.9	0
8	Subjective cognitive decline and self-reported sleep problems: The SCIENCE project. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	2.4	5
9	Neuropathology of <i>FMR1</i> -premutation carriers presenting with dementia and neuropsychiatric symptoms. <i>Brain Communications</i> , 2021, 3, fcab007.	3.3	7
10	Clinical Phenotypes of Behavioral Variant Frontotemporal Dementia by Age at Onset. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 381-390.	2.6	8
11	A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 106.	6.2	37
12	BDNF-Met polymorphism and amyloid-beta in relation to cognitive decline in cognitively normal elderly: the SCIENCE project. <i>Neurobiology of Aging</i> , 2021, 108, 146-154.	3.1	6
13	Can we improve clinical trial design in Alzheimer's disease? The participants point of view. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
14	Neuropsychiatric symptoms in patients with possible vascular cognitive impairment: Does sex matter?. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
15	Subjective cognitive decline and self-reported sleep at a memory clinic: The SCIENCE project. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
16	Cognitive decline in possible vascular cognitive impairment (VCI): Does the form of vascular brain injury matter?. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
17	Methylphenidate and galantamine in patients with vascular cognitive impairment—the proof-of-principle study STREAM-VCI. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 10.	6.2	10
18	Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 8.	6.2	12

#	ARTICLE	IF	CITATIONS
19	Comorbid amyloid β pathology affects clinical and imaging features in VCD. <i>Alzheimer's and Dementia</i> , 2020, 16, 354-364.	0.8	6
20	Dutch Brain Research Registry for online study participant recruitment: Design and first results. <i>Alzheimer's and Dementia</i> , 2020, 16, e044738.	0.8	0
21	Serum glial fibrillary acidic protein and neurofilament light as prognostic biomarkers for clinical progression in subjective cognitive decline: The SCIENCe project. <i>Alzheimer's and Dementia</i> , 2020, 16, e044783.	0.8	1
22	Neuropathology of FMR1 Δ premutation carriers presenting with dementia and neuropsychiatric symptoms. <i>Alzheimer's and Dementia</i> , 2020, 16, e044916.	0.8	0
23	Grey zone amyloid burden heralds future memory decline: The SCIENCe Project. <i>Alzheimer's and Dementia</i> , 2020, 16, e045210.	0.8	0
24	ATN classification and clinical progression in subjective cognitive decline. <i>Neurology</i> , 2020, 95, e46-e58.	1.1	97
25	Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project. <i>Neurobiology of Aging</i> , 2020, 89, 99-107.	3.1	34
26	Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions. <i>Neurobiology of Aging</i> , 2019, 84, 225-234.	3.1	42
27	Amyloid- β Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCe Project. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 7.	3.4	37
28	High amyloid burden is associated with fewer specific words during spontaneous speech in individuals with subjective cognitive decline. <i>Neuropsychologia</i> , 2019, 131, 184-192.	1.6	22
29	Dietary Patterns Are Related to Clinical Characteristics in Memory Clinic Patients with Subjective Cognitive Decline: The SCIENCe Project. <i>Nutrients</i> , 2019, 11, 1057.	4.1	10
30	Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 33.	6.2	30
31	How Do Different Forms of Vascular Brain Injury Relate to Cognition in a Memory Clinic Population: The TRACE-VCI Study. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1273-1286.	2.6	4
32	Clinical relevance of acute cerebral microinfarcts in vascular cognitive impairment. <i>Neurology</i> , 2019, 92, e1558-e1566.	1.1	24
33	The Clinical Phenotype of Vascular Cognitive Impairment in Patients with Type 2 Diabetes Mellitus. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 311-322.	2.6	16
34	Performance of five automated white matter hyperintensity segmentation methods in a multicenter dataset. <i>Scientific Reports</i> , 2019, 9, 16742.	3.3	38
35	Impact of white matter hyperintensity location on depressive symptoms in memory-clinic patients: a lesion-symptom mapping study. <i>Journal of Psychiatry and Neuroscience</i> , 2019, 44, E1-E10.	2.4	9
36	An exploratory clinical study of p38 β kinase inhibition in Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 464-473.	3.7	43

#	ARTICLE	IF	CITATIONS
37	A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline. <i>Human Brain Mapping</i> , 2018, 39, 3143-3151.	3.6	40
38	Microbleeds are associated with depressive symptoms in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 112-120.	2.4	7
39	O1â€14â€04: IMPACT OF WHITE MATTER HYPERINTENSITY LOCATION ON DEPRESSIVE SYMPTOMS IN MEMORY CLINIC PATIENTS: A LESIONâ€SYMPTOM MAPPING STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P259.	0.8	0
40	ICâ€Pâ€111: [¹⁸ F]FLORBETAPIRâ€SPECIFIC BINDING IN RELATION TO COGNITION IN SUBJECTIVE COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2018, 14, P95.	0.8	0
41	P1â€357: MEDIAN SURVIVAL IN MEMORY CLINIC COHORT IS SHORT, EVEN IN YOUNGâ€ONSET DEMENTIA. <i>Alzheimer's and Dementia</i> , 2018, 14, P431.	0.8	0
42	P1â€016: METHYLPHENIDATE IMPROVES EXECUTIVE FUNCTIONING IN PATIENTS WITH VASCULAR COGNITIVE IMPAIRMENT: FIRST RESULTS OF THE STREAMâ€VCI STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P270.	0.8	0
43	O2â€06â€03: AMYLOIDâ€LOAD IS RELATED TO WORRIES IN INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2018, 14, P632.	0.8	0
44	O2â€06â€01: [¹⁸ F]FLORBETAPIR SPECIFIC BINDING IN RELATION TO COGNITION IN SUBJECTIVE COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2018, 14, P630.	0.8	0
45	O2â€14â€04: IDENTIFYING BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA AMONG PATIENTS WITH A LATEâ€ONSET FRONTAL LOBE SYNDROME: SUMMARY RESULTS OF THE LOF STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P657.	0.8	0
46	P1â€602: DUTCH ONLINE REGISTRY FOR RECRUITMENT OF PARTICIPANTS FOR DEMENTIA STUDIES: HERSENONDERZOEK.NL AND BRAIN HEALTH REGISTRY. <i>Alzheimer's and Dementia</i> , 2018, 14, P569.	0.8	1
47	P3â€617: NUTRITIONAL INTAKE IN SUBJECTIVE COGNITIVE DECLINE: ROOM FOR IMPROVEMENT?. <i>Alzheimer's and Dementia</i> , 2018, 14, P1366.	0.8	0
48	F4â€08â€01: PLASMA AMYLOID AS A PREâ€SCREENING TOOL FOR AMYLOID POSITIVITY IN SUBJECTIVE COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1394.	0.8	0
49	Cerebral Blood Flow and Cognitive Functioning in a Community-Based, Multi-Ethnic Cohort: The SABRE Study. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 279.	3.4	61
50	Safety, tolerability and efficacy of the glutaminy cyclase inhibitor PQ912 in Alzheimerâ€™s disease: results of a randomized, double-blind, placebo-controlled phase 2a study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 107.	6.2	80
51	Subjective Cognitive Impairment Cohort (SCIENCE): study design and first results. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 76.	6.2	87
52	Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial. <i>JMIR Research Protocols</i> , 2018, 7, e80.	1.0	3
53	Screening for Mild Cognitive Impairment and Dementia with Automated, Anonymous Online and Telephone Cognitive Self-Tests. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 249-259.	2.6	18
54	Design of the ExCersionâ€VCI study: The effect of aerobic exercise on cerebral perfusion in patients with vascular cognitive impairment. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 157-165.	3.7	15

#	ARTICLE	IF	CITATIONS
55	Cerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatric disorders. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 7, 99-106.	2.4	32
56	The effect of hippocampal function, volume and connectivity on posterior cingulate cortex functioning during episodic memory fMRI in mild cognitive impairment. <i>European Radiology</i> , 2017, 27, 3716-3724.	4.5	28
57	The Pitfall of Behavioral Variant Frontotemporal Dementia Mimics Despite Multidisciplinary Application of the FTDC Criteria. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 959-975.	2.6	34
58	Lower cerebral blood flow in subjects with Alzheimer's dementia, mild cognitive impairment, and subjective cognitive decline using two-dimensional phase-contrast magnetic resonance imaging. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 9, 76-83.	2.4	39
59	Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 531-540.	0.8	99
60	Lower cerebral blood flow is associated with faster cognitive decline in Alzheimer's disease. <i>European Radiology</i> , 2017, 27, 1169-1175.	4.5	97
61	[P3422]: CLINICAL AND RADIOLOGICAL FINDINGS IN PATIENTS WITH PATHOLOGICALLY CONFIRMED CAA. <i>Alzheimer's and Dementia</i> , 2017, 13, P1127.	0.8	0
62	[P34095]: MICROBLEEDS ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P74.	0.8	0
63	[P34110]: GREY MATTER CONNECTIVITY IS RELATED TO A STEEPER LOSS OF MEMORY AND LANGUAGE FUNCTIONING OVER TIME IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2017, 13, P87.	0.8	0
64	[P24052]: THE DUTCH BRAIN HEALTH REGISTRY: OPTIMIZING RECRUITMENT FOR DEMENTIA RESEARCH. <i>Alzheimer's and Dementia</i> , 2017, 13, P624.	0.8	3
65	[P24211]: AMYLOID β 242 (A β 242) DIFFERENTIALLY CORRELATES WITH CSF TOTAL AND HYPERPHOSPHORYLATED TAU IN AN AMYLOID POSITIVE VERSUS AMYLOID NEGATIVE EARLY PRODROMAL AND ASYMPTOMATIC AT-RISK FOR AD POPULATION. <i>Alzheimer's and Dementia</i> , 2017, 13, P690.		0
66	[O140102]: MICROBLEEDS ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P182.	0.8	0
67	[O240101]: CHARACTERIZING INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE: THE SUBJECTIVE COGNITIVE IMPAIRMENT COHORT (SCIENCE). <i>Alzheimer's and Dementia</i> , 2017, 13, P547.	0.8	0
68	[O240906]: EVIDENCE THAT ORAL P38 MAPK ALPHA ANTAGONISM IMPROVES EPISODIC MEMORY IN PATIENTS WITH EARLY ALZHEIMER'S DISEASE (AD). <i>Alzheimer's and Dementia</i> , 2017, 13, P576.	0.8	0
69	Vascular Cognitive Impairment in a Memory Clinic Population: Rationale and Design of the Utrecht-Amsterdam Clinical Features and Prognosis in Vascular Cognitive Impairment (TRACE-VCI) Study. <i>JMIR Research Protocols</i> , 2017, 6, e60.	1.0	29
70	The Diagnostic Challenge of the Late-Onset Frontal Lobe Syndrome. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e1197-e1203.	2.2	18
71	Formal Psychiatric Disorders are not Overrepresented in Behavioral Variant Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 1249-1256.	2.6	12
72	P24221: Cerebral Blood Flow Measured with Phase-Contrast MRI in AD, MCI and Controls. <i>Alzheimer's and Dementia</i> , 2016, 12, P706.	0.8	0

#	ARTICLE	IF	CITATIONS
73	ICâ€Pâ€108: Cerebral Blood Flow Measured With Phaseâ€Contrast MRI in AD, MCI and Controls. Alzheimer's and Dementia, 2016, 12, P82.	0.8	0
74	Diagnostic Accuracy of the Frontotemporal Dementia Consensus Criteria in the Late-Onset Frontal Lobe Syndrome. Dementia and Geriatric Cognitive Disorders, 2016, 41, 210-219.	1.5	29
75	P4-159: Screening and Recruitment Experience When Using Biomarker-Based Population Definition in Alzheimerâ€™s Disease Studies. , 2016, 12, P1075-P1076.		0
76	Schizophrenia as a mimic of behavioral variant frontotemporal dementia. Neurocase, 2016, 22, 285-288.	0.6	12
77	Cerebral perfusion in the predementia stages of Alzheimerâ€™s disease. European Radiology, 2016, 26, 506-514.	4.5	99
78	P4-088: Lower cerebral blood flow is associated with cognitive decline in patients with Alzheimer's disease. , 2015, 11, P806-P806.		0
79	IC-P-079: Lower cerebral blood flow is associated with cognitive decline in patients with Alzheimer's disease. , 2015, 11, P57-P57.		0
80	P4-089: Lower cerebral blood flow is related to more severe cognitive impairment in patients with dementia due to Alzheimer's disease. , 2015, 11, P806-P807.		1
81	IC-P-062: Lower cerebral blood flow is related to more severe cognitive impairment in patients with dementia due to Alzheimer's disease. , 2015, 11, P46-P47.		0
82	White matter hyperintensities, cognitive impairment and dementia: an update. Nature Reviews Neurology, 2015, 11, 157-165.	10.1	811
83	Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinic. Alzheimer's and Dementia, 2015, 11, 523-532.	0.8	59
84	Microbleeds, Mortality, and Stroke in Alzheimer Disease. JAMA Neurology, 2015, 72, 539.	9.0	48
85	Identifying bvFTD Within the Wide Spectrum of Late Onset Frontal Lobe Syndrome: A Clinical Approach. American Journal of Geriatric Psychiatry, 2015, 23, 1056-1066.	1.2	26
86	White Matter Hyperintensities Relate to Clinical Progression in Subjective Cognitive Decline. Stroke, 2015, 46, 2661-2664.	2.0	73
87	Prevalence of cortical superficial siderosis in a memory clinic population. Neurology, 2014, 82, 698-704.	1.1	71
88	Cerebral small vessel disease affects white matter microstructure in mild cognitive impairment. Human Brain Mapping, 2014, 35, 2836-2851.	3.6	59
89	Brain volume and white matter hyperintensities as determinants of cerebral blood flow in Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2665-2670.	3.1	28
90	Building a New Paradigm for the Early Recognition of Behavioral Variant Frontotemporal Dementia: Late Onset Frontal Lobe Syndrome Study. American Journal of Geriatric Psychiatry, 2014, 22, 735-740.	1.2	30

#	ARTICLE	IF	CITATIONS
91	Optimizing Patient Care and Research: The Amsterdam Dementia Cohort. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 313-327.	2.6	307
92	P1-415: STUDY PROTOCOL: THE EFFECT OF PHYSICAL EXERCISE ON CEREBRAL BLOOD FLOW AND COGNITION IN PATIENTS WITH MILD VASCULAR COGNITIVE IMPAIRMENT. , 2014, 10, P465-P466.		0
93	Impact of molecular imaging on the diagnostic process in a memory clinic. <i>Alzheimer's and Dementia</i> , 2013, 9, 414-421.	0.8	159
94	Amyloid imaging in clinical trials. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 36.	6.2	18
95	The influence of cerebral small vessel disease on default mode network deactivation in mild cognitive impairment. <i>NeuroImage: Clinical</i> , 2013, 2, 33-42.	2.7	36
96	O1-09-01: Diagnostic impact of CSF biomarkers for Alzheimer's disease in a memory clinic setting. , 2013, 9, P144-P145.		0
97	Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 2488-2494.	3.1	66
98	Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the future. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 56.	6.2	51
99	Serum proteomics in amnesic mild cognitive impairment. <i>Proteomics</i> , 2013, 13, 2526-2533.	2.2	9
100	Associations between Magnetic Resonance Imaging Measures and Neuropsychological Impairment in Early and Late Onset Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 169-178.	2.6	21
101	Predictors of Progression from Mild Cognitive Impairment to Dementia in the Placebo-Arm of a Clinical Trial Population. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 79-85.	2.6	21
102	Episodic Memory Impairment in Frontotemporal Dementia; A ^{99m} Tc- HMPAO SPECT Study. <i>Current Alzheimer Research</i> , 2013, 10, 332-339.	1.4	11
103	Amyloid imaging in prodromal Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2011, 3, 26.	6.2	23
104	Can novel therapeutics halt the amyloid cascade?. <i>Alzheimer's Research and Therapy</i> , 2010, 2, 5.	6.2	19
105	MRI and CSF biomarkers in AD's accuracy and temporal change. <i>Nature Reviews Neurology</i> , 2010, 6, 650-651.	10.1	4
106	Glucocorticoid receptor variant and risk of dementia and white matter lesions. <i>Neurobiology of Aging</i> , 2008, 29, 716-723.	3.1	30
107	Progression of Cerebral Small Vessel Disease in Relation to Risk Factors and Cognitive Consequences. <i>Stroke</i> , 2008, 39, 2712-2719.	2.0	492
108	Plasma β amyloid and impaired CO ₂ -induced cerebral vasomotor reactivity. <i>Neurobiology of Aging</i> , 2007, 28, 707-712.	3.1	12

#	ARTICLE	IF	CITATIONS
109	Retinal vessel diameters and cerebral small vessel disease: the Rotterdam Scan Study. <i>Brain</i> , 2006, 129, 182-188.	7.6	203
110	Cerebral small-vessel disease and decline in information processing speed, executive function and memory. <i>Brain</i> , 2005, 128, 2034-2041.	7.6	646
111	Alcohol intake in relation to brain magnetic resonance imaging findings in older persons without dementia. <i>American Journal of Clinical Nutrition</i> , 2004, 80, 992-997.	4.7	86
112	Cerebral White Matter Lesions and the Risk of Dementia. <i>Archives of Neurology</i> , 2004, 61, 1531.	4.5	441
113	Plasma amyloid β , apolipoprotein E, lacunar infarcts, and white matter lesions. <i>Annals of Neurology</i> , 2004, 55, 570-575.	5.3	112
114	Silent Brain Infarcts and the Risk of Dementia and Cognitive Decline. <i>New England Journal of Medicine</i> , 2003, 348, 1215-1222.	27.0	2,037
115	Operational Definitions for the NINDS-AIREN Criteria for Vascular Dementia. <i>Stroke</i> , 2003, 34, 1907-1912.	2.0	158